Nextgen Biomed Ltd engages in research and development activities. It provides EyePen, a smart and modular device that consists of insulin injection pens and assists users in self-managing the diabetes treatment by recording the times and doses of insulin taken via injection it includes a camera, a voice-based monitoring system, a bluetooth component, a real-time image processor, connectivity and tracking of insulin injections using a dedicated mobile/computer/cloud application, based on AI that allows it to collect and manage information. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Rehovot, Israel.